MA52722A - Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation - Google Patents
Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisationInfo
- Publication number
- MA52722A MA52722A MA052722A MA52722A MA52722A MA 52722 A MA52722 A MA 52722A MA 052722 A MA052722 A MA 052722A MA 52722 A MA52722 A MA 52722A MA 52722 A MA52722 A MA 52722A
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- methods
- secretase inhibitors
- oxazine derivatives
- oxazine
- Prior art date
Links
- 239000002439 beta secretase inhibitor Substances 0.000 title 1
- 150000004893 oxazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434711P | 2016-12-15 | 2016-12-15 | |
| US201762570425P | 2017-10-10 | 2017-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52722A true MA52722A (fr) | 2021-04-14 |
Family
ID=60888744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052722A MA52722A (fr) | 2016-12-15 | 2017-12-13 | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10947223B2 (OSRAM) |
| EP (1) | EP3555080B1 (OSRAM) |
| JP (1) | JP7177773B2 (OSRAM) |
| AU (1) | AU2017376441B2 (OSRAM) |
| CA (1) | CA3047286A1 (OSRAM) |
| MA (1) | MA52722A (OSRAM) |
| MX (1) | MX388696B (OSRAM) |
| WO (1) | WO2018112081A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012129168A (ru) † | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| US11548903B2 (en) | 2016-12-15 | 2023-01-10 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047288A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| MA50007A (fr) | 2016-12-15 | 2021-04-07 | Amgen Inc | Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
| JP7353708B2 (ja) | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的ｂａｃｅ１阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| EP0871720A2 (en) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| CA2343004A1 (en) | 1998-09-24 | 2000-03-30 | Pharmacia & Upjohn Company | Alzheimer's disease secretase |
| US8173642B2 (en) * | 2005-10-25 | 2012-05-08 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| MX2009011498A (es) | 2007-04-24 | 2009-11-10 | Shionogi & Co | Derivados de aminodihidrotiazina sustituida con un grupo ciclico. |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| KR20110048491A (ko) | 2008-07-28 | 2011-05-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스피로아미노디하이드로티아진 유도체들 |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| ES2539859T3 (es) | 2008-09-30 | 2015-07-06 | Eisai R&D Management Co., Ltd. | Nuevo derivado de aminodihidrotiazina condensado |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
| WO2011070781A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| AU2012206555A1 (en) | 2011-01-12 | 2013-08-01 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| PH12013501480A1 (en) | 2011-01-13 | 2022-10-26 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| AU2012243329B2 (en) | 2011-04-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use |
| JPWO2012147762A1 (ja) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| EP2517898A1 (de) | 2011-04-29 | 2012-10-31 | Lanxess Deutschland GmbH | Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US8927535B2 (en) | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| WO2013028670A1 (en) | 2011-08-22 | 2013-02-28 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| AU2013235117A1 (en) * | 2012-03-20 | 2014-10-16 | Dean R. Artis | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof |
| JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| SI2912041T1 (sl) | 2012-10-26 | 2017-02-28 | Eli Lilly And Company | Derivati tetrahidropirolotiazina kot inhibitorji beta sekretaze (bace) |
| US9447085B2 (en) | 2012-12-14 | 2016-09-20 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use |
| EP2935256B1 (en) | 2012-12-19 | 2018-01-24 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
| JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2014099794A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors |
| WO2014099788A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
| EA201591614A1 (ru) * | 2013-03-08 | 2015-12-30 | Эмджен Инк. | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
| KR20170139060A (ko) | 2015-04-21 | 2017-12-18 | 올제네시스 바이오테라퓨틱스 아이엔씨. | Bace1 억제제로서의 화합물 및 이의 용도 |
| US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| MA50007A (fr) * | 2016-12-15 | 2021-04-07 | Amgen Inc | Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
| US11548903B2 (en) | 2016-12-15 | 2023-01-10 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047288A1 (en) * | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
-
2017
- 2017-12-13 US US16/466,211 patent/US10947223B2/en active Active
- 2017-12-13 WO PCT/US2017/066177 patent/WO2018112081A1/en not_active Ceased
- 2017-12-13 MX MX2019007101A patent/MX388696B/es unknown
- 2017-12-13 CA CA3047286A patent/CA3047286A1/en active Pending
- 2017-12-13 EP EP17822984.5A patent/EP3555080B1/en active Active
- 2017-12-13 MA MA052722A patent/MA52722A/fr unknown
- 2017-12-13 AU AU2017376441A patent/AU2017376441B2/en active Active
- 2017-12-13 JP JP2019531733A patent/JP7177773B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020503293A (ja) | 2020-01-30 |
| CA3047286A1 (en) | 2018-06-21 |
| US20200207747A1 (en) | 2020-07-02 |
| EP3555080B1 (en) | 2023-09-20 |
| AU2017376441A1 (en) | 2019-07-04 |
| US10947223B2 (en) | 2021-03-16 |
| WO2018112081A1 (en) | 2018-06-21 |
| MX2019007101A (es) | 2019-12-16 |
| EP3555080A1 (en) | 2019-10-23 |
| JP7177773B2 (ja) | 2022-11-24 |
| MX388696B (es) | 2025-03-20 |
| AU2017376441B2 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52722A (fr) | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA54101A (fr) | Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation | |
| MA53881A (fr) | Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 | |
| EP3377612A4 (en) | FUNCTIONAL EXPRESSION OF MONOOXYGENASES AND METHODS OF USE | |
| EP3352774A4 (en) | FLAVONOID COMPOSITIONS AND METHODS OF USE | |
| EP3504213A4 (en) | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHOD FOR USE THEREOF | |
| MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| EP3313404A4 (en) | THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE | |
| EP3778607C0 (en) | BENZOXAZEPINE-OXAZOLIDINONE COMPOUNDS AND METHOD OF USE | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3443094A4 (en) | PROCESS FOR REDUCING C9ORF72 EXPRESSION | |
| EP3394065A4 (en) | TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF | |
| EP3435956A4 (en) | Photo-stabilized compositions and methods of use | |
| EP3364968A4 (en) | OXAZOLIDINONE COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| EP3386927A4 (en) | POLYMERIC COMPOSITIONS AND METHODS OF USE | |
| MA50007A (fr) | Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation | |
| EP3302558A4 (en) | ANTI-TUMOR MEDIUM AND METHOD OF USE | |
| MA54100A (fr) | Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation | |
| EP3444254A4 (en) | HETEROCYCLICALLY SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | |
| EP3459323A4 (en) | Spray chambers and methods of using them |